Orexo in brief

Orexo develops improved specialty pharmaceuticals and treatments for new areas of use – at a lower cost, in a shorter period of time and at a lower risk – by combining known substances with patented proprietary technologies.

Launched products

Zubsolv® is a product for treatment of opioid dependence. On July 3, 2013, the product was approved for maintenance treatment by the U.S. Food and Drug Administration, FDA and on September 16, 2013, the product was launched on the US market. On August 10, 2015, FDA approved Zubsolv for induction of treatment of opioid dependence.

Abstral® is a product that provides rapid relief of breakthrough pain in cancer patients. In March 2013, Orexo sold the rights to Abstral in the United States to Galena Biopharma, Inc. As of November 2015 Galena divested its Abstral US business to Sentynl Therapeutics Inc. In September 2013, Abstral was approved in Japan. Orexo’s Japanese partner Kyowa Hakko Kirin Co., Ltd. holds the rights for Abstral in Japan. ProStrakan Group plc holds the product rights in the EU and the rest of the world.

Edluar® is a product for the treatment of short-term insomnia. The specialty pharma company Meda has a global license for Edluar.

Orexo previously marketed Diabact® UBT, Heliprobe® System and IRIS™ through its subsidiary Kibion. These products are used in the diagnosis of the gastric ulcer bacterium Helicobacter pylori. Kibion was divested as of April 30, 2015.

Development programs

OX51, prevention of acute pain during diagnostic and therapeutic procedures. OX51 is a novel sublingual formulation comprising alfentanil.

Collaboration projects

OX-MPI, PGE2-inhibition, treatment of inflammatoric pain. The aim with this project is to develop a completely new class of products based on Orexo's prostaglandin research. In August 2014, Orexo's partner Boehringer Ingelheim decided to return the OX-MPI (selective inhibition of prostaglandin E2 synthase) to Orexo. Boehringer Ingelheim had been responsible for all research and development within the OX-MPI project since 2005. Orexo still sees potential in the project due to a unique target, an identified development compound and several granted patents.
At the end of 2015, the process of identifying a new external partner for OX-MPI was ongoing.

Other projects

Orexo continues to leverage its competences within pharmaceutical formulation and has projects aiming at developing new formulation platforms. At the end of 2015, these projects were still in the exploratory phases.